Carotid intima-media thickness as a surrogate marker of cardiovascular disease in diabetes

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Background:

Diabetes mellitus is associated with a high risk of cardiovascular disease. Carotid intima-media thickness (CIMT) is increasingly used as a surrogate marker for atherosclerosis. Its use relies on its ability to predict future clinical cardiovascular end points.

Methods:

This review examines the evidence linking CIMT as a surrogate marker of vascular complications in people with type 1 and type 2 diabetes. We have also reviewed the various treatment strategies which have been shown to influence CIMT.

Conclusions:

CIMT measurement is an effective, noninvasive tool which can assist in identifying people with diabetes who are at higher risk of developing microvascular and macrovascular complications. It may also help to evaluate the effectiveness of various treatment strategies used to treat people with diabetes.

Related collections

Most cited references 138

Record: found
Abstract: found
Article: not found

Diabetes and cardiovascular disease. The Framingham study.

W Kannel, D McGee (1979)

Based on 20 years of surveillance of the Framingham cohort relating subsequent cardiovascular events to prior evidence of diabetes, a twofold to threefold increased risk of clinical atherosclerotic disease was reported. The relative impact was greatest for intermittent claudication (IC) and congestive heart failure (CHF) and least for coronary heart disease (CHD), which was, nevertheless, on an absolute scale the chief sequela. The relative impact was substantially greater for women than for men. For each of the cardiovascular diseases (CVD), morbidity and mortality were higher for diabetic women than for nondiabetic men. After adjustment for other associated risk factors, the relative impact of diabetes on CHD, IC, or stroke incidence was the same for women as for men; for CVD death and CHF, it was greater for women. Cardiovascular mortality was actually about as great for diabetic women as for diabetic men.

0 comments Cited 492 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.

Jean-Louis Chiasson, Robert G Josse, Ramon Gomis … (2002)

The worldwide increase in type 2 diabetes mellitus is becoming a major health concern. We aimed to assess the effect of acarbose in preventing or delaying conversion of impaired glucose tolerance to type 2 diabetes. In a multicentre, placebo-controlled randomised trial, we randomly allocated patients with impaired glucose tolerance to 100 mg acarbose or placebo three times daily. The primary endpoint was development of diabetes on the basis of a yearly oral glucose tolerance test (OGTT). Analyses were by intention to treat. We randomly allocated 714 patients with impaired glucose tolerance to acarbose and 715 to placebo. We excluded 61 (4%) patients because they did not have impaired glucose tolerance or had no postrandomisation data. 211 (31%) of 682 patients in the acarbose group and 130 (19%) of 686 on placebo discontinued treatment early. 221 (32%) patients randomised to acarbose and 285 (42%) randomised to placebo developed diabetes (relative hazard 0.75 [95% CI 0.63-0.90]; p=0.0015). Furthermore, acarbose significantly increased reversion of impaired glucose tolerance to normal glucose tolerance (p<0.0001). At the end of the study, treatment with placebo for 3 months was associated with an increase in conversion of impaired glucose tolerance to diabetes. The most frequent side-effects to acarbose treatment were flatulence and diarrhoea. Acarbose could be used, either as an alternative or in addition to changes in lifestyle, to delay development of type 2 diabetes in patients with impaired glucose tolerance.

0 comments Cited 425 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial.

J Stamler, O Vaccaro, J Neaton … (1993)

To assess predictors of CVD mortality among men with and without diabetes and to assess the independent effect of diabetes on the risk of CVD death. Participants in this cohort study were screened from 1973 to 1975; vital status has been ascertained over an average of 12 yr of follow-up (range 11-13 yr). Participants were 347,978 men aged 35-57 yr, screened in 20 centers for MRFIT. The outcome measure was CVD mortality. Among 5163 men who reported taking medication for diabetes, 1092 deaths (603 CVD deaths) occurred in an average of 12 yr of follow-up. Among 342,815 men not taking medication for diabetes, 20,867 deaths were identified, 8965 ascribed to CVD. Absolute risk of CVD death was much higher for diabetic than nondiabetic men of every age stratum, ethnic background, and risk factor level--overall three times higher, with adjustment for age, race, income, serum cholesterol level, sBP, and reported number of cigarettes/day (P < 0.0001). For men both with and without diabetes, serum cholesterol level, sBP, and cigarette smoking were significant predictors of CVD mortality. For diabetic men with higher values for each risk factor and their combinations, absolute risk of CVD death increased more steeply than for nondiabetic men, so that absolute excess risk for diabetic men was progressively greater than for nondiabetic men with higher risk factor levels. These findings emphasize the importance of rigorous sustained intervention in people with diabetes to control blood pressure, lower serum cholesterol, and abolish cigarette smoking, and the importance of considering nutritional-hygienic approaches on a mass scale to prevent diabetes.

0 comments Cited 342 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Journal

Journal ID (nlm-ta): Diabetes Metab Syndr Obes

Title: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

Publisher: Dove Medical Press

ISSN (Electronic): 1178-7007

Publication date Collection: 2011

Publication date (Electronic): 19 January 2011

Volume: 4

Pages: 23-34

Affiliations

[1 ]Wolfson Diabetes and Endocrine Clinic, Addenbrooke’s Hospital, Cambridge, UK;

[2 ]Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK

Author notes

Correspondence: Latika Sibal, Wolfson Diabetes and Endocrine Clinic, Institue of Metabolic Science, Box 281, Addenbrooke’s Hospital, Hill’s Road, Cambridge CB2 0QQ, UK, Tel +44 7766445165, Email latikasibal@ 123456hotmail.com

Article

Publisher ID: dmso-4-023

DOI: 10.2147/DMSO.S8540

PMC ID: 3064409

PubMed ID: 21448319

SO-VID: 51fa8bdc-e0a6-41de-88d7-0dd76db40648

License:

This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.

Carotid intima-media thickness as a surrogate marker of cardiovascular disease in diabetes

Read this article at

Abstract

Background:

Methods:

Conclusions:

Related collections

Bioscientifica Open Endocrinology

Most cited references 138

Diabetes and cardiovascular disease. The Framingham study.

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial.

Author and article information

Journal

Affiliations

Author notes

Article

History

Categories

Comments

Comment on this article

Similar content 590

Cited by 32

Most referenced authors 2,269